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Hypertension increases the risk for a variety of cardiovascular diseases, including stroke, coronary artery disease, heart failure, and
peripheral vascular disease. The increase in oxidative stress has been associated with the pathogenesis of hypertension. Increase
of blood pressure is due to an imbalance between antioxidants defence mechanisms and free radical productions. Excessive
production of reactive oxygen species reduces nitric oxide bioavailability leading to an endothelial dysfunction and a subsequent
increase in total peripheral resistance. Hypertension can cause few symptoms until it reaches the advanced stage and poses serious
health problems with lifelong consequences. Hypertensive patients are required to take drugs for life to control the hypertension
and prevent complications. Some of these drugs are expensive and may have adverse reactions. Hence, it is timely to examine
scientifically, complimentary therapies that are more effective and with minimal undesirable effects. Nigella sativa (NS) and its
active constituents have been documented to exhibit antioxidant, hypotensive, calcium channel blockade and diuretic properties
which may contribute to reduce blood pressure. This suggests a potential role of NS in the management of hypertension, and thus
more studies should be conducted to evaluate its effectiveness.
1. Introduction
According to The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation and Treat-
ment of High Blood Pressure, hypertension is diagnosed as
systolic blood pressure (BP) which is greater than 140mmHg
and/or diastolic BP which is greater than 90mmHg [1]. The
prevalence of hypertension in most developing countries is
comparable to the developed countries [2, 3]. Hypertension
is a major global health disorder due to prolonged human
life span. Familial influence and environmental factors such
as obesity, sedentary life style, and unhealthy dietary habit
contribute to the high prevalence of hypertension [4–6]. The
prevalence of hypertension in Malaysians aged 30 years and
above was 42.6% in year 2006, a relative increase of 30%
compared to 10 years earlier [7]. In the year 2000, it was
estimated about 972 million world’s adult population had
hypertension.This number will increase to 1.56 billion by the
year 2025 [8].
In recent years, there has been a growing interest and
demand in usingmedicinal plants for treating and preventing
various diseases including cardiovascular diseases. Tradi-
tional medicines of plants origin have received much atten-
tion due to several factors such as easy availability, affordable
cost, safety, and efficacy as well as cultural acceptability.
Nigella sativa (NS), or also known as black cumin or its Arabic
name habat-ul sauda, has been used for centuries in medic-
inal and culinary purposes throughout the Middle East,
India, and Northern Africa. It is an annual flowering plant
with pale blue flowers that belongs to the Ranunculaceae
family. The plant has a fruit which contains angular black
seeds, and the seeds are considered to be the most valuable
part contributing beneficial health effects. NS as a natural
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remedy has been documented to possess numerous therapeu-
tic values, including diabetes, tumour, hypercholesterolemia,
hypertension, inflammation, and gastrointestinal disorders
[9–14].The present paper is, therefore, to examine the current
literature on the cardiovascular protective effects of NS and
its constituents against oxidative stress and hypertension in
addition to the possible mechanisms of actions underlying
these beneficial effects.
2. Nigella sativa (NS)
The seed oil of NS was found to be rich in polyphenols
and tocopherols [25, 26]. The seeds contain 36–38% fixed
oils, 0.4–2.5% essential (volatile) oil, proteins, alkaloids, and
saponins [27].The fixed oil is composedmainly of fatty acids,
namely, linoleic (C18:2), oleic (C18:1), palmitic (C16:0), and
stearic (C18:0) acids [28]. Thymoquinone (TQ) is the most
pharmacologically active ingredient found abundantly (30–
48%) in the black seeds, together with its derivatives such as
dithymoquinone, thymohydroquinone, and thymol [29].
3. Antioxidant Property of NS
The seed oil of NS is well known for its strong antioxidant
properties [30]. Previous studies have documented that pre-
treatment with TQ, the main active constituents in seed
oil, protected organs against oxidative damage induced by a
variety of free radical generating agents, such as carbon tetra-
chloride [31] and including the alkylating agents, cisplatin
[32], and doxorubicin [33].The free radical scavenging effects
of TQ, dithymoquinone, and thymol were tested against
several reactive oxygen species (ROS) [34]. All the tested
compounds from NS exerted strong antioxidant effects;
thymol acted as singlet oxygen quencher, while TQ and
dithymoquinone showed superoxide dismutase (SOD)-like
activity [34]. In addition, a study carried out by Mansour
et al. [35] revealed that both TQ and dithymoquinone
acted not only as superoxide anion scavengers, but also as
general free radical scavengers with half maximal inhibitory
concentration (IC
50
) in the nanomolar and micromolar
ranges, respectively.These findings suggest the importance of
such free radical scavenging compounds in the treatment of
hypertensionwhich is closely associatedwith oxidative stress.
TQ is a potent superoxide radical scavenger which is
as effective as SOD against superoxides generated either
photochemically, biochemically, or derived from calcium
ionophore (A23817) [36]. Furthermore, TQ has an inhibitory
effect on lipid peroxidation induced by Fe3+/ascorbate. In
rats, TQ is protective against doxorubicin-induced cardiotox-
icity by reducing the elevation of serum lactate dehydro-
genase and creatine phosphokinase levels [36]. Ismail et al.
[37] showed that both TQ-rich fraction and TQ markedly
improved plasma antioxidant status by inhibiting formation
of hydroxyl radicals. Moreover, liver antioxidant enzymes
(SOD and glutathione peroxidase GPx) are significantly
increased in rats treated with TQ-rich fraction and TQ. In
the same study, both TQ-rich fraction and TQ caused an
enhanced expression of antioxidant genes (SOD-1, catalase
CAT, and GPx-2) in hypercholesterolemic rats [37].
Ers¸ahin et al. [38] reported that NS oil with its potent
free radical scavenging properties, inhibited subarachnoid-
haemorrhage-(SAH-) induced lipid peroxidation of the brain
tissue in rat against the reactive hydroxyl, peroxyl, and
superoxide radicals. In addition, the level of antioxidant
glutathione (GSH) was preserved [38], thereby ameliorating
oxidative damage. The SAH-induced reduction of Na+/K+-
ATPase activity indicated the presence of membrane damage.
The Na+/K+-ATPase is involved in the generation of the
membrane potential through the active transport of sodium
and potassium ions in cellular membrane. It maintains
neuronal excitability and controls cellular volume in the
central nervous system. Treatment with NS oil was able to
restore Na+/K+-ATPase activity back to normal levels [38].
Administration of TQ restored the activities of nonen-
zymatic (GSH and vitamin C) and enzymatic (SOD, CAT,
GPx, and glutathione-S-transferase GST) antioxidants as well
as reduced the levels of malondialdehyde (MDA) in the rat
brain to normal levels [39]. Besides that, TQ supplemen-
tation resulted in a complete reversal of the gentamicin-
(GM-) induced increase in blood urea nitrogen, creatinine,
thiobarbituric acid reactive substances (TBARS), and nitric
oxide (NO) and decrease in GSH, GPx, CAT, and adenosine
triphosphate (ATP) to control values [40]. Histopathological
examination of kidney tissues was in agreement with the
biochemical data, wherein TQ supplementation prevented
GM-induced degenerative changes in kidney tissues [40].The
findings from this study demonstrated the strong protective
effect of TQ by its ability to decrease oxidative stress and to
preserve the activities of the antioxidant enzymes [40].
4. Pathogenesis of Hypertension
4.1. Role of Oxidative Stress in Hypertension. Free radicals
possess one or more unpaired electrons in their outer elec-
tronic orbits. ROS such as superoxide anion (O
2
−), hydroxyl
radical (OH−), hydrogen peroxide (H
2
O
2
), and singlet oxy-
gen (1O
2
) are highly reactive. Free radicals and ROS are
formed continuously in normal physiological process [41].
However, excessive production leads to oxidative stress with
an increase in the formation of nitrogen-oxygen derivative
free radicals as well as a decrease in antioxidant capacity [42].
Oxidative stress occurs when there is an imbalance
between production of ROS and antioxidant defence system
in favour of the former [43, 44]. ROS are highly reactive and
unstable by nature; hence, they can damage various cellular
components including lipid membranes. Lipid peroxides are
derived from polyunsaturated fatty acid (PUFA) oxidation
and are capable to initiate lipid peroxidation via free radicals
chain reaction. MDA is a major end product of PUFA
peroxidation and is often used as an indicator of cell injury.
Increase in the production of MDA may be due to the
formation of reactive oxidants. Lipid peroxidation leads to
structural changes of the lipid molecules, and the changes are
more severe as lipids are the main constituent of biological
membranes. Generally, lipid peroxides pose a risk factor
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for atherosclerotic complications. Increase in free radical
formation is linked to a reduction in NO generation [45].
Elevation in serumMDA level found in hypertensive patients
suggests a relationship with the increased oxidative stress
[46].
Endothelium-derived relaxing factor (EDRF) or better
known as NO plays an important regulatory role in the
maintenance of vascular homeostasis. BP is regulated by
cardiac output and peripheral resistance of blood vessels. NO
causes vasodilatation, subsequently reducing total periph-
eral resistance. Endothelial dysfunction is associated with
abnormal endothelium-dependent relaxation as observed in
hypertension [47–49]. Reduced NO bioavailability, that is, a
reduction in NO production by free radicals or an increase
in deactivation of NO due to imbalance between antioxi-
dant and oxidant levels may be the mechanism underlying
endothelium dysfunction.
NO is synthesized predominantly in the vascular
endothelium. Endothelial nitric oxide synthase (eNOS) is
required for the synthesis of NO from amino acid L-arginine.
There are two other isoforms of NOS, namely, neuronal nitric
oxide synthase (nNOS) and inducible nitric oxide synthase
(iNOS). Both eNOS and nNOS are constitutive enzymes that
are produced in normal physiological process, while iNOS
is mainly induced during inflammation. NO is small in size
and lipophilic by nature. This allows NO to diffuse rapidly
through cell membranes to the adjacent smooth muscle
cells. Eventually, NO activates guanylate cyclase (GC), and
stimulates the formation of cyclic guanosine monophosphate
(cGMP) that leads to vascular smooth muscle relaxation.
Generation of ROS such as superoxide anions may cause
cellular injury by oxidizing membrane lipids, proteins, and
nucleic acids. Furthermore, superoxide anions may reduce
NO bioavailability by binding to the gaseous molecule and
forming peroxynitrite which itself is a free radical [50].
Angiotensin-converting enzyme (ACE) plays a vital role
in the regulation of BP and electrolytes balance. ACE is
mainly located on the surface of endothelium and epithelium.
It hydrolyses angiotensin I (Ang I) to angiotensin II (Ang II), a
potent vasoconstrictor and aldosterone-stimulating peptide.
Ang II is an important factor in cardiovascular homeostasis
[51]. The importance of ACE in maintaining the BP can be
observed via the beneficial effect of ACE inhibitors in treating
hypertension [52, 53]. Ang II induces oxidative stress via acti-
vation of nicotinamide adenine dinucleotide/nicotinamide
adenine dinucleotide phosphate (NADH/NADPH) oxidase
and the production of ROS [54]. In addition to that, Ang
II increases lipid peroxidation [55] and stimulates the pro-
duction of prooxidant cytokines [56, 57], in which these
subsequently lead to elevation of BP. Ang II decreases NOS
expression and stimulates the generation of ROS [54].
Ang II-induced hypertension is associated with increased
vascular superoxide production and impaired vasorelaxation
to acetylcholine [54]. Ang II exacerbates oxidative stress,
and the increase in the superoxide level could result in
endothelial dysfunction via scavenging NO and decreasing
NO bioavailability [58]. Hence, the NO-Ang II imbalance
may be an important component in the vascular pathophys-
iology of hypertension. Ang II has been suggested to cause
an increase in oxidized low-density lipoprotein cholesterol
(ox-LDL) uptake, eventually causing endothelial cell injury
[59]. On the other hand, it has also been suggested that
ox-LDL upregulates Ang II type 1 receptor expression [60].
These observations may indicate the presence of a relation-
ship between ox-LDL and rennin-angiotensin systems in
hypertension. Hence, these two systems may be responsible
for the development of endothelial dysfunction, leading to an
increase in BP.
4.2. Evidences of Oxidative Stress Involved in Hypertension.
There has been a growth evidence suggesting that hyper-
tension may be attributable to the increased production of
ROS [61, 62]. Oxidative stress may play a vital role in the
development of hypertension via the following mechanisms:
enhanced sequestration of NO by ROS [63], formation of
lipid peroxidation products [64], and depletion ofNOS cofac-
tor (tetrahydrobiopterin) [65]. Lastly, it may cause functional
and structural changes in vascular wall and blood vessel
[66]. These vascular alterations may be mediated by several
ways, including direct injury to endothelial and vascular
smooth muscle cells, effects on endothelial cell eicosanoid
metabolism, altered redox state, increases in intracellular
free calcium concentration, stimulation of inflammatory, and
growth signalling events [67, 68].
Oxidative stress promotes proliferation of vascular
smooth muscle cells as well as collagen deposition which
cause thickening of tunica media and narrowing of the
vascular lumen [69], which eventually leads to an increase
in the total peripheral resistance. Furthermore, increase
in oxidative stress may damage the endothelium and
impair endothelium-dependent vasodilatation, consequently
increasing vascular contractile activity [69]. ROS may also
induce endothelial permeability with the recruitment of
inflammatory protein and cells, in which can compromise
endothelial function and worsen vascular damage [70]. All
these observed effects on the vasculature further support the
pathological role of oxidative stress in hypertension.
Amanullah et al. [70] reported that higher MDA levels
and lower antioxidant activities such as SOD, GSH, and
GPx in hypertensive subjects may be due to increased
production of free radicals, indicating the presence of oxida-
tive stress in hypertension. There were notable a positive
correlation between BP and lipid peroxidation products in
the hypertensives and a negative correlations between BP
with plasma antioxidant capacity, plasma vitamin C levels,
erythrocyte activity of antioxidant enzymes, and erythrocyte
reduced/oxidized glutathione (GSH/GSSG) ratio [71]. These
findings demonstrated a possible role of oxidative stress in the
pathophysiology of hypertension. In another study, hyperten-
sive patients exhibited higher plasma lipid peroxides along
with decreased nonenzymatic antioxidant levels, which could
be associated with oxidative stress and depleted antioxidant
defence potential [72]. Oxidative stress may occur due to
a reduction in antioxidant activities or due to an elevation
in ROS concentration. This can lead to oxidative damage
to the structure of biomolecules which mostly involve the
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Table 1: Significant cardiovascular effects of NS and its constituents.
Reference Study model Constituents Laboratory findings
[12] Renovascular hypertensive rat NS oil (i.p.)0.2mL/kg
↓ SBP, tissue MDA, luminol, and
lucigenin CL
↑ tissue Na+ and K+-ATPase
↓ plasma CK, LDH, and ADMA
↑ plasma NO
[15] Rat
(a) NS oil (i.v.)
4–32 𝜇L/kg
(b) TQ (i.v.)
0.2–1.6mg/kg
↓ arterial BP and heart rate
(dose dependent)
[16] Guinea pig NS oil (i.v.)4–32 𝜇L/kg
↓ arterial BP and heart rate
(dose dependent)
[17] Rat
(a) De-TQ volatile oil (i.v.)
2–16 𝜇L/kg
(b) 𝛼-pinene (i.v.)
1–4𝜇L/kg
(c) p-cymene (i.v.)
2–16 𝜇L/kg
↓ arterial BP and heart rate
(dose dependent)
∗De-TQ volatile oil and p-cymene:
4, 8, and 16 𝜇L/kg
∗𝛼-pinene:
2 and 4𝜇L/kg
[18] Rat Thymol(in vitro)
↓ aortic contraction
(dose dependent)
[19] Canine and guinea pig Thymol(in vitro)
Negative inotropic action
(dose dependent)
[20] Spontaneously hypertensive rat NS seed extract (p.o.)0.6mL/kg
↑ diuresis
↓ arterial BP
[21] Spontaneously hypertensive rat NS extract (p.o.) ↓ SBP
↑ GFR, urinary and electrolyte output
[22] L-NAME-inducedhypertensive rat
TQ (p.o.)
0.5mg/kg and
1mg/kg
↓ SBP and serum creatinine
↑ kidney GSH
[23] L-NAME-induced hypertensiverat
NS seed extract (p.o.)
400mg/kg
↓ arterial BP, SBP, DBP, and serum LDH
↑ serum NO
[24] Patients with mild hypertension
NS seed extract (p.o.)
100mg/kg and
200mg/kg
↓ SBP and DBP
(dose dependent)
↓ total and LDL cholesterol
NS: Nigella sativa; L-NAME: L-NG-nitroarginine methyl ester; i.p.: intraperitoneal; i.v.: intravenous; p.o.: per os; TQ: thymoquinone; De-TQ: de-
thymoquinonated; SBP: systolic blood pressure; DBP: diastolic blood pressure; MDA: malondialdehyde; CL: chemiluminescence; CK: creatine kinase;
LDH: lactate dehydrogenase; ADMA: asymmetric dimethylarginine; NO: nitric oxide; GFR: glomerular filtration rate; GSH: glutathione; LDL: low-density
lipoprotein.
antioxidant enzymes, thus contributing to the oxidative stress
in hypertensives instead of normotensive subjects.
A variety of antioxidant treatments ameliorate hyperten-
sion in animal and human studies. Veratric acid, a phenolic
acid, was found to decrease the BP, significantly restored NO,
enzymatic and nonenzymatic antioxidants, and reduced lipid
peroxidation products against L-NG-nitroarginine methyl
ester-(L-NAME-) induced hypertension in Wistar rats [73].
Park et al. [74] demonstrated that soy isoflavone supplemen-
tation elevated serum NO and total radical trapping antiox-
idant potential (TRAP) with a reduction in systolic BP after
30 days of feeding period to spontaneously hypertensive rats
(SHRs).The results suggest that protective effect of isoflavone
against hypertension occurs possibly via the mitigation of
oxidative stress and augmentation of NO production. Con-
sumption of green tea which possess strong antioxidant
polyphenols was able to reduce BP, serum tumour necrosis
factor-𝛼, c-reactive protein, and triglycerides, and total and
low-density lipoprotein cholesterol while increasing total
antioxidant status and high-density lipoprotein cholesterol in
patients with obesity-related hypertension [75].
Administration of vitamins C and E for eight weeks in
patients with essential hypertension (EH) had significantly
lowered systolic BP, diastolic BP, and mean arterial pressure
compared to placebo [76]. The BP reduction was associated
with higher erythrocyte and serum antioxidant capacity. BP
correlated positively with plasma 8-isoprostane levels and
negativelywith ferric reducing ability of plasma (FRAP) levels
in the vitamins C and E and placebo-treated groups [76].The
findings support the view that oxidative stress is involved in
the pathogenesis of EH and that enhancement of antioxidant
status by supplementation with vitamins C and E in patients
with EH is associated with reduced BP. Hence, this suggests
that intervention with antioxidants is a potential adjunct
therapy for hypertension.
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Figure 1: Proposed pathways forNigella sativa (NS) in reducing blood pressure (BP). Ca2+, calcium (II) ion; Na+, sodium ion; K+, potassium
ion; Cl−, chloride ion; HR, heart rate; CO, cardiac output; TPR, total peripheral resistance.
5. Possible Pharmacological Actions of NS
against Hypertension
The exact mechanism on how NS reduces BP is not exactly
known. The antihypertensive effects of NS may be due to the
many active compounds, each with distinct mechanisms of
actions.There are several possiblemechanisms involved inBP
reduction, which include cardiac depressant effect, calcium
channels blocking property, and diuretic effect. Table 1 sum-
marized the effects of NS and its active compounds on BP.
5.1. Cardiac Depressant. Previous studies reported that the
volatile oil and TQ decreased both the arterial BP and
heart rate [15, 16]. The effects of NS on BP and heart rate
were reversed by cyproheptadine (a nonselective serotonin
receptor blocker) and atropine (antimuscarinic M
2
agent)
[15, 16]. This finding suggests that the protective effects of NS
were mainly mediated centrally either directly or indirectly
via mechanisms involving serotoninergic and muscarinic
receptors [15, 16]. In contrary, El-Tahir et al. [17] docu-
mented that de-thymoquinonated volatile oil, 𝛼-pinene, and
p-cymene from NS reduced BP and heart rate. However,
hypotensive effect of NS was not reversed by atropine or
cyproheptadine although these two drugs antagonized the
effect of NS on heart rate [17].
The cardiac depressant effects of NS in the rats were sig-
nificantly reversed by hexamethonium (a ganglionic blocker)
suggesting amechanism involving nicotinic receptors [17]. In
addition, destruction of connection between the vasomotor
centre in the medulla and preganglionic sympathetic by
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spinal pithing prevented NS-induced cardiovascular changes
[17].Therefore, the cardiac depressant and hypotensive effects
of NS appeared to be mediated via central mechanism
involving vasomotor centre in the medulla and sympathetic
outflow to the periphery.
Failure of indomethacin (prostaglandin cyclooxygenase
inhibitor), mepacrine and hydrocortisone (phospholipase
A
2
inhibitor), mepyramine (histamine H
1
receptor blocker),
ranitidine (histamine H
2
receptor blocker), and methylene
blue (NO-cGMP formation antagonist) to affect NS-induced
cardiovascular depressant effects suggests a lack of involve-
ment of eicosanoid, histaminergic, platelet-activating factor
(PAF), and NO-induced mechanisms [17].
5.2. CalciumChannel Blockade. Thymol, another active com-
pound of NS, has been documented to be able to reduce
BP via its action on calcium (Ca2+) ion channels. Peixoto-
Neves et al. [18] reported that thymol produced dose-
dependent relaxation in rat isolated aorta. The NS-induced
endothelium-independent relaxation may be mediated via
mechanisms involving inhibition of Ca2+ release from sar-
coplasmic reticulum, reduced Ca2+ sensitivity of the con-
tractile system, and/or blockade of Ca2+ influx across the
membrane [18]. Thymol induced a dose-dependent negative
inotropic action on both canine and guinea-pig isolated
cardiac preparations [19]. The observed effect may be due
to a decrease in Ca2+ content in sarcoplasmic reticulum via
inhibition of Ca2+ channel [19]. Effect of thymol on Ca2+
current in human and canine ventricular cardiomyocytes was
investigated. Magyar et al. [77] demonstrated that thymol
inhibits L-type Ca2+ current in a dose-dependent manner.
When Ca2+ channels are blocked, Ca2+ entry into vascular
smooth muscles is reduced eventually leading to an increase
in vasorelaxation.
5.3. Diuretic. The kidney plays a vital role in the control of
BP and in the pathogenesis of hypertension. Zaoui et al. [20]
reported that 0.6mL/kg of NS extract for 15 days caused 16%
increase in diuresis in SHRs. The diuretic effect of NS was
comparable to 5mg/kg of furosemide which is a high ceiling
diuretic.The diuretic effect was associated with an increase in
urinary excretion ofNa+, K+, Cl−, and urea [20].This suggests
that NS may decrease BP via its diuretic action. A reduction
in electrolytes and water content leading to decrease in blood
volume, which subsequently reducing cardiac output, is one
of the main determinants for BP regulation. In another study,
NS extract also demonstrated similar results with an increase
in glomerular filtration rate, urinary, and electrolyte output
[21]. Rennin-angiotensin-aldosterone (RAA) systems may
contribute in regulating BP by controlling blood volume
and peripheral vascular resistance. However, the observed
effects of NS extract neither have influence on plasma ACE
nor rennin activities of SHRs after 20 days of treatment
[21]. Therefore, antihypertensive action of NS seems to be
independent of RAA system.Nevertheless, more studies need
to be performed to evaluate this hypothesis.
6. Conclusion
The cardiovascular protective effects of NS in hypertension
are possibly contributed by its multitude actions includ-
ing cardiac depressant, diuretic, calcium channel blockade,
and antioxidant properties (Figure 1). NS is a promising
medicinal plant with many therapeutic properties. Various
studies have documented the protective effects of NS on the
cardiovascular system against the damaging effects of various
ROS, protecting the heart from cardiotoxicity as well as
reducing adverse effects due toROS involved in hypertension.
NS has been used as a traditional medicine for the treatment
of hypertension for many years with no report of adverse
events. Further studies should be carried out on human to
confirm its efficacy. It is an important area for further research
and development to combine NS with other antihypertensive
drugs to investigate their possible synergistic effects and
preferable pharmacological properties.
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